

1 Platelet Storage – Current limitations and future 2 solutions

3 4 5 ABSTRACT

6 Platelets are small anucleate cell fragments found in the blood, which originate from large cells known as megakaryocytes. Platelets are widely used in transfusion medicine for therapeutic purposes. Platelet transfusions are beneficial for patients who are experiencing thrombocytopenic conditions or heavy bleeding and demands for platelet concentrates (PCs) are constantly on the rise. Current regulations that govern how PC units are prepared require that these be stored at a temperature of $22^{\circ}\text{C}\pm 2^{\circ}\text{C}$, under constant agitation for 5 days. This short shelf-life is due to the high susceptibility of this product to bacterial contaminations and platelet storage lesions (PSL). Many publications demonstrate how storing PCs at lower temperatures may help increase the shelf-life of this blood product. Prolonging the shelf-life will consequently decrease unnecessary wastage of valuable donations and the overall costs associated with PC production. Furthermore, cold stored platelets decrease both the risk of bacterial contamination and the occurrence of PSL.

7
8 *Keywords: Platelet Concentrates, cold storage, prolonged shelf-life, quality, safety*

9 10 1. INTRODUCTION

11 Platelet transfusion is considered an essential part of therapeutics and is beneficial for
12 patients who are either suffering from a thrombocytopenic condition or experiencing heavy
13 bleeding, which could be either due to trauma or surgery(1). Platelet concentrates (PCs) act
14 by preventing further haemorrhage in affected individuals. Due to its wide range of essential
15 purposes, PCs are constantly requested in high demands. In fact, in Europe and in the
16 United States of America, approximately 5 million PCs are administered annually(2).

17 18 2. CURRENT STORAGE AND LIMITATIONS

19 As per the European Directorate for the Quality of Medicines and HealthCare guidelines, the
20 general storage conditions currently implemented by blood banks for PCs is a temperature
21 of $22^{\circ}\text{C}\pm 2^{\circ}\text{C}$, with constant agitation inside sterile gas-permeable bags and surfaces. To
22 date, depending on national regulations, such conditions provide a maximum shelf-life of
23 approximately 5 days. This may be extended up to 7 days if sterility testing is performed(3).
24 These storage conditions, however, present some limitations, namely the high risk of
25 pathogen contamination, as well as the occurrence of platelet storage lesions (PSL). PCs
26 stored at a temperature of $22^{\circ}\text{C}\pm 2^{\circ}\text{C}$ are highly susceptible to microbial contamination, since
27 the optimum temperature for most bacterial species to proliferate is at around 20°C (4).
28 Bacterial contamination may lead to the introduction of life-threatening infections, which lead
29 to sepsis, thus causing harm to patients(5). PSL is a condition triggered by the processing of
30 PCs and may occur at any point in time between collection and transfusion, whereby
31 platelets undergo an alteration in their morphology, functionality, and metabolic
32 mechanism(6). In the event of such lesions, transfused platelets may not deliver an
33 adequate therapeutic effect *in vivo*(7). **In view of this, no standard testing parameters are
34 being considered(8).**

35 Such aforementioned limitations minimize the PC's shelf-life, and a short shelf-life will result
36 in increased unnecessary wastage of expired PC units, decreased availability of PCs and an
37 increased sense of pressure to keep up with high demands. Several publications illustrated
38 the extent of such issues. It had been reported that the mean annual discard percentage
39 amongst seventeen different clinics, located in several different countries around the world,

40 was 13%(9). Another publication revealed that the discard percentage in Australia alone was
41 around 20%(10). Moreover, the production of such units is costly, which makes wastage a
42 major financial loss.

43

44 **3. COLD STORAGE – A POSSIBLE SOLUTION**

45 Over the years, several different methods have been implemented in the hope of reducing
46 PC wastage and enhancing product availability. An alternative approach, first introduced in
47 the medical field back in the 1960s, was storing PCs at a temperature of $4\pm 2^{\circ}\text{C}$. During this
48 period, it was common practice to store all PCs in the cold, however, such a method was
49 abandoned in the 1970s, due to newly emerged findings. Such findings suggested that
50 although cold-stored platelets resulted to be superior to room temperature stored platelets
51 through *in vitro* evaluations, these resulted to be inferior through *in vivo* evaluations(11).
52 Hence, platelets were once again stored at the conventional $22\pm 2^{\circ}\text{C}$ and this method of
53 storage has been in place ever since, up until recently. Currently, the possibility of utilising
54 cold-storage is being explored once again in several research studies and clinical trials.

55 Cold-stored PCs are slowly regaining popularity due to their ability to reduce the two main
56 issues which limit their shelf-life, that is, bacterial contamination and PSL. Several studies
57 are currently testing and demonstrating the various benefits of cold-stored platelets.
58 Analyses are being performed to assess both the *in vitro* and the *in vivo* qualities of the cold-
59 stored PCs. The wide range of *in vitro* and *in vivo* analyses, conducted in several different
60 studies, on cold-stored platelets provide key findings regarding the impact that low
61 temperatures have on platelets. The various outcomes derived were evaluated and
62 interpreted accordingly in order to determine the underlying principles involved, and to
63 establish whether platelet functions were preserved, diminished, or enhanced when
64 compared to traditional storage. These findings, hence, allowed for the discovery of both the
65 benefits and drawbacks of cold storage.

66

67 **3.1 The evidence so far**

68 The several different assessments performed have provided a wide range of significant
69 information regarding the *in vitro* qualities of cold-stored platelets(12). It was found that upon
70 lowering the temperature, metabolic processes within platelets were significantly slowed
71 down(1,7,13,14). The slowdown of metabolism consequently lead to a reduced consumption
72 of glucose and decreased production of lactate acid(15,16). In fact, through *in vitro* analyses,
73 it was found that pH levels in cold stored PCs were relatively maintained, when compared to
74 room temperature-stored PCs. Low pH levels led to the development of alterations in the
75 platelets, and thus, loss of functionality and viability(17). This implies, therefore, that platelet
76 integrity was better preserved at colder temperatures. It was estimated that the phenotype of
77 cold-stored platelets was maintained for up to 10-14 days(14,18). Moreover, a temperature
78 decrease, also led to a decline in microbial metabolism (19). This consequently reduced the
79 rate of proliferation, and hence, the risk of the occurrence of bacterial contamination in the
80 PCs. This has been demonstrated through several different studies(2,13). After
81 approximately 5 days of storage, platelet density and platelet count in room temperature-
82 stored PCs were found to be lower than those in cold-stored PCs(13,14). Such a finding
83 further demonstrates how lower temperatures are able to better safeguard the *in vitro*
84 qualities and parameters of the platelets. Additional *in vitro* analyses showed that
85 mitochondrial function was significantly maintained in cold-stored platelets(2,15,18). Studies
86 demonstrated how ATP generation by the mitochondria plays an essential role in platelet
87 integrity, function, and viability(20). Mitochondrial viability could be calculated by the
88 measurement of Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS)
89 generation following stimulation by an agonist. It was found that levels of ROS and RNS in
90 cold-stored platelets were greater than those in room temperature-stored platelets. This
91 implies that cold-stored platelets would be more capable of becoming activated in the
92 presence of an agonist. In fact, *in vitro* aggregation tests demonstrated that upon stimulation

93 with agonists, such as thrombin, ADP, collagen, alpha adrenergic and epinephrine, cold-
 94 stored platelets exhibited improved aggregation(17,21). In addition to this, the clots formed
 95 by cold-stored platelets upon aggregation, were found to be approximately 2.5 times stiffer
 96 than clots formed by platelets stored at room temperature and morphological analysis
 97 revealed that clots were denser and possessed greater crosslinks. Studies showed that this
 98 could have occurred due to the presence of factor XIII, which adhered to platelets upon
 99 exposure to lower temperatures(22). The increase in the amount of crosslinks could be
 100 explained through the presence of a greater amount of branching in clots produced by the
 101 platelets(23). Through macroscopic examinations of the units, it was also evident that unlike
 102 in room temperature-stored platelets, swirling - a simple test performed to evaluate
 103 morphology with the naked eye, was not seen in cold-stored platelets(15). This occurred
 104 since at a temperature below 15°C, platelets lose their conventional morphology, and shift
 105 from a discoid into a spherical shape(17,24). Furthermore evidence shows that at a colder
 106 temperature the platelet membrane is irreversibly damaged, subsequently causing
 107 phagocytosis of the platelets post transfusion(25).
 108 *In vivo* assessments were also essential in providing information regarding how the platelets
 109 function once they are transfused. It was found that thrombin generation was increased
 110 when using cold-stored platelets(7). This enhanced thrombin generation, hence, led to a
 111 rapid activation process. In fact, it was found by several different studies that clots from cold-
 112 stored platelets formed significantly faster(2,7,13), consequently reducing bleeding times in
 113 actively bleeding patients by up to 40%(18). Therefore, cold-stored platelets showed an
 114 improved hemostatic response. However, on the other hand, it was found that transfused
 115 cold-stored platelets possessed a relatively reduced recovery rate. In fact, a study conducted
 116 in the early 1970s demonstrated that after just one hour post-transfusion, only 45% of the
 117 transfused platelets were recovered(26). It was estimated that the lifespan of cold-stored
 118 platelets was approximately a quarter of that of room temperature-stored platelets(13), with
 119 the half-life of room temperature-stored platelets being 3.8 days and that of cold-stored
 120 platelets being approximately 1.8 days(27). Such a short lifespan stems from the fact that
 121 the clearance rate of such platelets from the circulation was highly accelerated. A study
 122 highlights the fact that under low temperatures, platelets undergo modifications such as actin
 123 rearrangement, glycan clustering and lipid raft aggregation, which may influence the
 124 platelets' lifespan in the recipient's circulation(17). Furthermore, a study conducted in
 125 Germany demonstrated that cold stored platelets express a greater amount of apoptotic
 126 markers than room temperature-stored platelets, thus, making them more susceptible to an
 127 elevated clearance rate(28).
 128 After evaluating the aforementioned significant findings, it was evident that cold-stored
 129 platelets possess a variety of both advantages and disadvantages. As can be visualized in
 130 Table 1, clinical trials demonstrated that although cold-stored platelets may present with
 131 some drawbacks such as a high clearance rate and a short lifespan *in vivo*, they also
 132 possess a wide range of benefits, which seem to outweigh the disadvantages
 133 acknowledged.
 134

Advantages	
PC pH levels are maintained due to a slowdown in metabolism	(17)
The risk of bacterial contamination is reduced at lower temperatures	(2,13,15)
Mitochondrial function in cold-stored platelets is maintained	(20)
Platelets are more capable to become activated in the presence of an agonist	(17,21)
Stiffer clots are formed upon activation	(22)
Cold-stored platelets show an improved haemostatic response	(18)
A high clearance rate minimizes the risk of thrombosis	(7)

Prevents platelet functional defects and reduced effectiveness, which (6)
normally occur at room temperature

Disadvantages

Short lifespan due to a high clearance rate *in vivo* following transfusion, (13,26–28)
hence requiring multiple transfusions

Low temperatures may cause alterations in platelet morphology (17,24)

Swirling not seen in cold stored platelets (15)

Table 1: Relative merits of cold-stored platelets

135

136

137

3.2. Additional Considerations

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

4. CONCLUSION

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

Patients requiring PC transfusions may be categorized into two main groups: chronic thrombocytopenic patients, such as cancer patients, who are unable to produce enough platelets, and patients who are suffering from acute bleeding either due to a traumatic injury, childbirth, or surgery(32), but are otherwise able to produce their own platelets. In the case of acutely bleeding patients, a rapid hemostatic response would be required. As aforementioned, cold-stored platelets are able to provide such response with the formation of strong clots. This is ideal for acutely bleeding patients since a fast reaction would be needed to slow down the blood loss. On the other hand, in the case of chronic thrombocytopenic patients, a longer platelet lifespan would be required, since individuals would be dependent on the action of the platelets being transfused. In such cases, once the transfused platelets are cleared, subsequent transfusions would be needed. Unlike chronic thrombocytopenic patients, acutely bleeding patients will not require platelets with long lifespans since once the transfused platelets are cleared, the body would be able to produce its own platelets to maintain hemostasis. Due to such different requirements, it is being widely suggested that cold-stored PC transfusions are used for acutely bleeding patients, whilst room temperature-stored platelets are utilised for chronic thrombocytopenic patients(10). This will allow product management to be always dependent on the needs of the individual receiving the transfusion. Furthermore, studies are being conducted and

180 results are showing that adequate *in vitro* qualities are still maintained when PCs are stored
181 at room temperature for the initial four days and then transferred to cold storage for the
182 remaining sixteen days(33). Therefore, a system may be introduced whereby expired room
183 temperature PCs, which are not used for chronic thrombocytopenic patients are transferred
184 to lower temperatures and used for acutely bleeding patients, instead of being discarded
185 after just five days.

186

187 **COMPETING INTERESTS**

188 Authors have declared that no competing interests exist

189

190 **AUTHORS' CONTRIBUTIONS**

191 All Authors contributed equality to the script, and all have read and approved the final
192 manuscript.

193

194 **CONSENT**

195 Not applicable

196

197 **ETHICAL APPROVAL**

198 Not applicable

199

200 **REFERENCES**

- 201 1. D'Alessandro A, Thomas KA, Stefanoni D, Gamboni F, Shea SM, Reisz JA, et
202 al. Metabolic phenotypes of standard and cold-stored platelets. *Transfusion*.
203 2020 Jun;60 Suppl 3:S96–106.
- 204 2. Hegde S, Akbar H, Zheng Y, Cancelas JA. Towards increasing shelf life and
205 haemostatic potency of stored platelet concentrates. *Curr Opin Hematol*. 2018
206 Nov;25(6):500–8.
- 207 3. European Directorate for the Quality of Medicines and Healthcare. 2020 [cited
208 2022 Aug 23]. Available from: <https://www.edqm.eu/en/>
- 209 4. Nichols CM, Bowman JP, Guezennec J. Effects of incubation temperature on
210 growth and production of exopolysaccharides by an antarctic sea ice bacterium
211 grown in batch culture. *Appl Environ Microbiol*. 2005 Jul;71(7):3519–23.
- 212 5. Liu V, Turk BJ, Rizk NW, Kipnis P, Escobar GJ. The association between sepsis
213 and potential medical injury among hospitalized patients. *Chest*. 2012
214 Sep;142(3):606–13.
- 215 6. Ng MSY, Tung JP, Fraser JF. Platelet Storage Lesions: What More Do We
216 Know Now? *Transfus Med Rev*. 2018 Apr 17;S0887-7963(17)30189-X.
- 217 7. Javed R, Jawed A. Promising platelets: potential benefits and extended life-
218 span of cold-stored and cryopreserved platelets. *AJMS*. 2019 Jan 1;12(1):1–3.
- 219 8. Grech K, Baron B, Zammit V. Storage of Platelet Concentrates - Looking
220 Beyond Standard Parameters for Prolonged Storage. 2021 Oct 29;4:1024.

- 221 9. Kreuger AL, Caram-Deelder C, Jacobse J, Kerkhoffs JL, van der Bom JG,
222 Middelburg RA. Effect of storage time of platelet products on clinical outcomes
223 after transfusion: a systematic review and meta-analyses. *Vox Sang*. 2017
224 May;112(4):291–300.
- 225 10. Johnson L, Waters L, Green S, Wood B, Marks DC. Freezing expired platelets
226 does not compromise in vitro quality: An opportunity to maximize inventory
227 potential. *Transfusion*. 2020 Mar;60(3):454–9.
- 228 11. Miles J, Bailey SL, Fang L, Osborne B, Corson J, Mack JP, et al. Evaluation of
229 Efficacy and Safety of Cold-Stored Platelets in Healthy Human Subjects Treated
230 with Dual Antiplatelet Therapy. *Blood*. 2019 Nov 13;134(Supplement_1):718.
- 231 12. Capraru A, Jalowiec KA, Medri C, Daskalakis M, Zeerleder SS, Mansouri
232 Taleghani B. Platelet Transfusion-Insights from Current Practice to Future
233 Development. *J Clin Med*. 2021 May 6;10(9):1990.
- 234 13. Reddoch KM, Pidcoke HF, Montgomery RK, Fedyk CG, Aden JK,
235 Ramasubramanian AK, et al. Hemostatic function of apheresis platelets stored
236 at 4°C and 22°C. *Shock*. 2014 May;41 Suppl 1:54–61.
- 237 14. Johnson L, Vekariya S, Tan S, Padula MP, Marks DC. Extended storage of
238 thawed platelets: Refrigeration supports postthaw quality for 10 days.
239 *Transfusion*. 2020 Dec;60(12):2969–81.
- 240 15. Braathen H, Sivertsen J, Lunde THF, Kristoffersen EK, Assmus J, Hervig TA, et
241 al. In vitro quality and platelet function of cold and delayed cold storage of
242 apheresis platelet concentrates in platelet additive solution for 21 days.
243 *Transfusion*. 2019 Aug;59(8):2652–61.
- 244 16. Haines JM, Hwang JK, Wardrop KJ. The effects of additive solutions on the
245 development of storage lesions in stored canine platelet concentrates. *J Vet
246 Emerg Crit Care (San Antonio)*. 2021 Mar;31(2):247–55.
- 247 17. Vit G, Klüter H, Wuchter P. Platelet storage and functional integrity. *Journal of
248 Laboratory Medicine*. 2020 Oct 1;44(5):285–93.
- 249 18. Strandenes G, Sivertsen J, Bjerkvig CK, Fosse TK, Cap AP, Del Junco DJ, et al.
250 A Pilot Trial of Platelets Stored Cold versus at Room Temperature for Complex
251 Cardiothoracic Surgery. *Anesthesiology*. 2020 Dec 1;133(6):1173–83.
- 252 19. Price PB, Sowers T. Temperature dependence of metabolic rates for microbial
253 growth, maintenance, and survival. *Proc Natl Acad Sci U S A*. 2004 Mar
254 30;101(13):4631–6.
- 255 20. Bynum JA, Meledeo MA, Getz TM, Rodriguez AC, Aden JK, Cap AP, et al.
256 Bioenergetic profiling of platelet mitochondria during storage: 4°C storage
257 extends platelet mitochondrial function and viability. *Transfusion*. 2016 Mar;56
258 Suppl 1:S76-84.

- 259 21. Montgomery RK, Reddoch KM, Evani SJ, Cap AP, Ramasubramanian AK.
260 Enhanced shear-induced platelet aggregation due to low-temperature storage.
261 *Transfusion*. 2013 Jul;53(7):1520–30.
- 262 22. Nair PM, Pandya SG, Dallo SF, Reddoch KM, Montgomery RK, Pidcoke HF, et
263 al. Platelets stored at 4°C contribute to superior clot properties compared to
264 current standard-of-care through fibrin-crosslinking. *Br J Haematol*. 2017
265 Jul;178(1):119–29.
- 266 23. Javed. Precious platelets: The utility of cold-stored and cryopreserved platelets
267 [Internet]. [cited 2022 Aug 23]. Available from:
268 [https://www.gjtmonline.com/article.asp?issn=2468-](https://www.gjtmonline.com/article.asp?issn=2468-8398;year=2020;volume=5;issue=1;spage=17;epage=21;aualast=Javed)
269 [8398;year=2020;volume=5;issue=1;spage=17;epage=21;aualast=Javed](https://www.gjtmonline.com/article.asp?issn=2468-8398;year=2020;volume=5;issue=1;spage=17;epage=21;aualast=Javed)
- 270 24. Zhao H, Devine DV. The Missing Pieces to the Cold-Stored Platelet Puzzle. *Int*
271 *J Mol Sci*. 2022 Jan 20;23(3):1100.
- 272 25. Thomas S. Platelets: handle with care. *Transfusion Medicine*. 2016;26(5):330–
273 8.
- 274 26. Becker GA, Tuccelli M, Kunicki T, Chalos MK, Aster RH. Studies of platelet
275 concentrates stored at 22 C nad 4 C. *Transfusion*. 1973 Mar;13(2):61–8.
- 276 27. Murphy S, Gardner FH. Effect of storage temperature on maintenance of
277 platelet viability--deleterious effect of refrigerated storage. *N Engl J Med*. 1969
278 May 15;280(20):1094–8.
- 279 28. Marini I, Aurich K, Jouni R, Nowak-Harnau S, Hartwich O, Greinacher A, et al.
280 Cold storage of platelets in additive solution: the impact of residual plasma in
281 apheresis platelet concentrates. *Haematologica*. 2019 Jan;104(1):207–14.
- 282 29. Ashorobi D, Ameer MA, Fernandez R. Thrombosis [Internet]. *StatPearls*
283 [Internet]. StatPearls Publishing; 2022 [cited 2022 Aug 23]. Available from:
284 <https://www.ncbi.nlm.nih.gov/books/NBK538430/>
- 285 30. van Ree R, Hummelshøj L, Plantinga M, Poulsen LK, Swindle E. Allergic
286 sensitization: host-immune factors. *Clinical and Translational Allergy*. 2014 Apr
287 15;4(1):12.
- 288 31. Pfaff WW, Howard RJ, Scornik JC, Day C, Renderer J, Scott J, et al. Incidental
289 and purposeful random donor blood transfusion. *Sensitization and*
290 *transplantation*. *Transplantation*. 1989 Jan;47(1):130–3.
- 291 32. Sauerwein K. For bleeding patients, can cold storage of platelets improve blood
292 clotting? [Internet]. Washington University School of Medicine in St. Louis. 2021
293 [cited 2022 Aug 23]. Available from: [https://medicine.wustl.edu/news/for-](https://medicine.wustl.edu/news/for-bleeding-patients-can-cold-storage-of-platelets-improve-blood-clotting/)
294 [bleeding-patients-can-cold-storage-of-platelets-improve-blood-clotting/](https://medicine.wustl.edu/news/for-bleeding-patients-can-cold-storage-of-platelets-improve-blood-clotting/)

295 33. Wood B, Johnson L, Hyland RA, Marks DC. Maximising platelet availability by
296 delaying cold storage. *Vox Sang*. 2018 Apr 6;13(5):403–11.

297